greeksoup/ stock research

Surgery Partners (SGRY) Q3 FY2023 earnings: revenue $674 million, up 8.6% on the year

Surgery Partners, Inc. (SGRY) reported revenue of $674 million for Q3 FY2023, the quarter ended 30 September 2023, up 8.6% on the same quarter a year earlier. Net income was -$5 million, and diluted earnings per share $-0.04. The figures are the company's own, from the 10-Q it filed with the SEC on 7 November 2023.

Revenue$674 millionup 8.6%
Net income-$5 million
Diluted EPS$-0.04
QuarterQ3 FY2023ended 30 September 2023

The quarter, against the one before and a year earlier

LineQ3 FY2023Q2 FY2023Q3 FY2022Change on the year
Revenue674668621+8.6%
Operating income82.697.674.1+11.5%
Operating margin12.3%14.6%11.9%
Income tax3.1-7.87.8-60.3%
Net income-4.918.9-25.0n/a
Net margin-0.7%2.8%-4.0%
Diluted EPS-$0.04$0.15-$0.28n/a
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ3 FY2023Q2 FY2023Q3 FY2022Change on the year
Operating cash flow10552.129.7+252.2%
Capital expenditure18.925.817.3+9.2%
Free cash flow85.726.312.4+591.1%
Free cash flow margin12.7%3.9%2.0%
Cash from investing-25.6-71.2-54.3n/a
Cash from financing-20.4-49.0-48.0n/a
Depreciation and amortisation28.924.429.8-3.0%
Share-based compensation4.44.65.0-12.0%
Diluted shares, weighted126m127m89m+41.4%
Shares outstanding at period end126m126m90m+40.6%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ3 FY2023Q2 FY2023Q3 FY2022Change on the year
Shareholders' equity2,0052,0181,173+70.9%
Non-controlling interest982965932+5.3%
Redeemable equity332328339-1.9%
Debt2,7022,5703,220-16.1%
Operating lease liabilities241264270-10.7%
Finance lease liabilities616504564+9.4%
Other liabilitiesn/an/a39.5n/a
Total liabilities and equity6,7806,6216,536+3.7%
Goodwill4,2454,2364,145+2.4%
Cash and equivalents236177155+52.5%
Receivables463450422+9.6%
Inventory69.470.368.6+1.2%
Other assets1,7671,6871,746+1.2%
Total assets6,7806,6216,536+3.7%

Questions

What was Surgery Partners' revenue in Q3 FY2023?

Surgery Partners (SGRY) reported revenue of $674 million for Q3 FY2023, the quarter ended 30 September 2023, up 8.6% on the same quarter a year earlier.

How much did Surgery Partners earn in Q3 FY2023?

Net loss for Q3 FY2023 was $5 million, and the diluted loss per share $0.04.

When did Surgery Partners report Q3 FY2023 results?

Surgery Partners filed its 10-Q for the quarter ended 30 September 2023 with the SEC on 7 November 2023.

Quarterly results, the last 20 quarters

Q3 FY2021Q4 FY2021 *Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026
Revenue559610596615621707666668674735717762770864776826822885811849
Operating income63.611510076.574.194.246.497.682.610176.084.860.912761.911210611065.8102
Operating margin11%19%17%12%12%13%7%15%12%14%11%11%8%15%8%14%13%12%8%12%
Net income-22.9-0.112.2-18.4-25.0-23.4-24.918.9-4.9-1.0-12.4-15.5-31.7-108-37.7-2.5-22.7-15.0-35.9-15.0
Net margin-4%-0%2%-3%-4%-3%-4%3%-1%-0%-2%-2%-4%-13%-5%-0%-3%-2%-4%-2%
Diluted EPS-$0.28$0.12$0.14-$0.21-$0.28-$0.23-$0.20$0.15-$0.04-$0.01-$0.10-$0.12-$0.25-$0.86-$0.30-$0.02-$0.18-$0.12-$0.28-$0.12
Operating cash flow14.919.779.842.129.77.274.552.110562.640.782.865.21116.081.383.610311.759.3
Capital expenditure15.514.118.222.417.322.724.325.818.919.821.026.920.222.322.723.419.812.816.021.8
Free cash flow-0.65.661.619.712.4-15.550.226.385.742.819.755.945.089.1-16.757.963.890.6-4.337.5
Shares outstanding82m89m90m90m90m126m126m126m126m127m127m127m127m127m128m128m129m129m131m131m
Filing10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2023, filed 7 November 2023: the filing.